These findings support the results of an earlier published systemic review and meta‐analysis.20 According to Holdenrieder and colleagues, changes from pretreatment CEA levels during treatment are indicative of treatment response in NSCLC. The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.